Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
The next CMS Physicians, Nurses & Allied Professionals Open Door Forum is scheduled for Wednesday January 29, 2020 from 2:00 – 3:00 PM ET. Agenda and conference call information is provided below: Agenda: Opening Remarks Announcements: Announcement on New Prior Authorization Process Open Payment The Importance of Diagnosis Reporting and Physician Documentation under the PDGM Open Q & A Open Door Participation Instructions:
ASCO hosted the January 2020 PracticeNET call on January 16. Access to the agenda and slides are now available. Please visit the ASCO Practice Engagement Program page for more information about ASCO's wide selection of practice-focused programs, or email our Practice Engagement Director Chris LoBiondo.
On January 9, 2020, the Food and Drug Administration approved avapritinib (AYVAKITTM, Blueprint Medicines Corporation) for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V mutations. Read more. 
On January 8, 2020, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. Read more. 
In the latest ASCO in Action Podcast, ASCO CEO Dr. Clifford A. Hudis is joined by Dr. Jeffrey Ward, a leading contributor to the society’s updated Patient-Centered Oncology Payment (PCOP) model, to discuss how PCOP can improve care delivery and lowers costs. “If we don’t find a way to bend the cost curve, we’re not going to be able to fulfill the mission to take care of our patients,” said Dr. Ward. Take the ASCO Podcast Survey and help improve our podcasts.
The Centers for Medicare & Medicaid (CMS) recently discovered and corrected inconsistencies in the data after releasing final 2019 Merit-based Incentive Payment System (MIPS) eligibility data.  If you checked your eligibility following the December 4th listserv announcing final MIPS eligibility, your status may have been affected by the data inconsistencies.
Save the date for this 2-part webinar on FDA audit readiness, which will take participants on a journey through the FDA inspection process. The webinars will share experiences to make FDA inspections less daunting. The first webinar, taking place February 13 will include reflections from FDA and a principal investigator, who will share case studies and lessons learned on site selection and the investigator role. The second webinar, date to be announced, will offer strategies for effective pre-audit preparation and post-audit follow-up.
On December 27, 2019, the Food and Drug Administration approved olaparib (LYNPARZA®, AstraZeneca Pharmaceuticals LP) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma, as detected by an FDA-approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.